<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/42/6627" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/42/6627/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/42/6627/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_6627"><akn:num>6627</akn:num><akn:heading>Federally-funded research with enhanced pathogens of pandemic potential</akn:heading><akn:content><akn:p>§ 6627. Federally-funded research with enhanced pathogens of pandemic potential(a) Review and oversight of enhanced pathogens of pandemic potential(1) In generalThe Director of the Office of Science and Technology Policy (referred to in this section as the “Director”), in consultation with the heads of relevant Federal departments and agencies, shall—(A) not later than 1 year after December 29, 2022—(i) continue or conduct a review of existing Federal policies related to research proposed for Federal funding that may be reasonably anticipated to involve the creation, transfer, or use of enhanced pathogens of pandemic potential; and

(ii) establish or update a Federal policy for the consistent review and oversight of such proposed research that appropriately considers the risks associated with, and potential benefits of, such research; and


(B) not less than every 4 years thereafter, review and update such policy, as necessary and appropriate, to ensure that such policy fully accounts for relevant research that may be reasonably anticipated to involve the creation, transfer, or use of enhanced pathogens of pandemic potential, takes into consideration the benefits of such research, and supports the mitigation of related risks.


(2) RequirementsThe policy established pursuant to paragraph (1) shall include—(A) a clear scope to support the consistent identification of research proposals subject to such policy by relevant Federal departments and agencies;

(B) a framework for such reviews that accounts for safety, security, and ethical considerations related to the creation, transfer, or use of enhanced pathogens of pandemic potential;

(C) measures to enhance the transparency and public availability of information related to such research activities in a manner that does not compromise national security, the safety and security of such research activities, or any identifiable, sensitive information of relevant individuals; and

(D) consistent procedures across relevan</akn:p></akn:content><akn:subsection eId="subsec_6627_a"><akn:num>(a)</akn:num><akn:heading>Review and oversight of enhanced pathogens of pandemic potential</akn:heading><akn:content><akn:p>(a) Review and oversight of enhanced pathogens of pandemic potential</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_6627_b"><akn:num>(b)</akn:num><akn:heading>Implementation</akn:heading><akn:content><akn:p>(b) Implementation</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_6627_c"><akn:num>(c)</akn:num><akn:heading>Limitations on countries of concern conducting certain research</akn:heading><akn:content><akn:p>(c) Limitations on countries of concern conducting certain research</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>